{{'Search' | translate}}
 

MidiMACS Separator

MidiMACS分离器

Company: Miltenyi Biotec
Catalog#: 130-042-302
Bio-protocol()
Company-protocol()
Other protocol()

Modeling NOTCH1 driven T-cell Acute Lymphoblastic Leukemia in Mice
Author:
Date:
2020-05-20
[Abstract]   T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that arises from transformation of T-cell primed hematopoietic progenitors. Although T-ALL is a heterogenous and molecularly complex disease, more than 65% of T-ALL patients carry activating mutations in the NOTCH1 gene. The majority of T-ALL–associated NOTCH1 mutations either disrupt the negative regulatory region, allowing signal activation in the absence of ligand binding, or result in truncation of the C-terminal PEST domain involved in the termination of NOTCH1 signaling by proteasomal degradation. To date, retroviral transduction models have relied heavily on the overexpression of aggressively truncated variants of NOTCH1 (such as ICN1 or ΔE-NOTCH1), which result in ... [摘要]  [摘要 ] T细胞急性淋巴细胞白血病(T-ALL)是一种侵袭性血液恶性肿瘤,其起源于T细胞引发的造血祖细胞的转化。尽管T-ALL是一种异质且分子复杂的疾病,但超过65%的T-ALL患者在NOTCH1 基因中带有激活突变。大多数与T-ALL相关的NOTCH1 突变要么破坏负调控区,允许在没有配体结合的情况下激活信号,要么导致蛋白酶体降解终止NOTCH1信号终止所涉及的C末端PEST域被截短。迄今为止,逆转录病毒转导模型在很大程度上依赖于侵袭性截短的变种的过度表达。 NOTCH1 (例如ICN1或ΔE-NOTCH1)可导致信号传导的超生理水平,并且在人类T-ALL中很少见。当前方案描述了小鼠骨髓分离,造血干细胞和祖细胞(HSC)富集,然后逆转录病毒转导的致癌突变体形式的NOTCH1受体(NOTCH1-L1601P-ΔP)的方法,该方法与获功能突变最常见于患者样品中。组成型活性NOTCH1的这种强制表达的标志是胸腺外未成熟T细胞发育的瞬时波,此波在致癌性转化为T-ALL之前。此外,该方法通过允许白血病细胞与微环境之间的串扰来模拟体内白血病的转化和进展,这是基于细胞系的体外研究无法解释的一个方面。因此,HSC转导和移植模型更真实地概括了人类疾病的发展,为进一步的体内和离体功能研究提供了高度全面和通用的工具。

[背景 ] ...

Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas
Author:
Date:
2018-04-05
[Abstract]  Pituitary adenomas are among the more frequent intracranial tumors usually treated with both surgical and pharmacological–based on somatostatin and dopamine agonists–approaches. Although mostly benign tumors, the occurrence of invasive behaviors is often detected resulting in poorer prognosis. The use of primary cultures from human pituitary adenomas represented a significant advancement in the knowledge of the mechanisms of their development and in the definition of the determinants of their pharmacological sensitivity. Moreover, recent studies identified also in pituitary adenomas putative tumor stem cells representing, according to the current hypothesis, the real cellular targets to eradicate most malignancies. In this protocol, we describe the procedure to establish primary cultures ... [摘要]  垂体腺瘤是更常见的颅内肿瘤之一,通常用基于生长抑素和多巴胺激动剂手术的手术和药物治疗。 虽然多为良性肿瘤,但侵入性行为的发生常常被检测到,导致预后较差。 来自人类垂体腺瘤的原代培养物的使用代表了对其发育机制的知识以及其药理敏感性决定因素的定义方面的显着进步。 此外,最近的研究也在垂体腺瘤中发现了假定的肿瘤干细胞,根据目前的假设,它代表了根除大多数恶性肿瘤的真实细胞靶标。 在这个协议中,我们描述了从人垂体腺瘤建立原代培养的程序,以及如何选择,体外扩增和表型鉴定推定的垂体腺瘤干细胞。

【背景】垂体腺瘤是最常见的颅内肿瘤之一(高达15%),横断面研究发现每100,000名居民中约有90例发病,其中绝大多数为30岁以上的成年人。大约10%的未经选择的垂体在尸检时进行了检查(即考虑到之前未诊断为垂体疾病的受试者的垂体)( ,Molitch,2017)。尽管通常为良性肿瘤,但垂体腺瘤的处理可因与激素分泌过多相关的临床综合征或发展以治疗抗性,高增殖率,快速复发和绒毛外侵袭为特征的侵袭行为而复杂化(Carreno等人,2017)。成年垂体干细胞的持续存在(Florio,2011)导致垂体腺瘤(以及可能的其他良性瘤形成)的发展可以源自具有干细胞特性(主要是自我更新和分化)的肿瘤细胞的亚群能力),正如已经建立的恶性固体和血液肿瘤一样。

最近的实验证据表明,癌症干细胞(CSC)范例也适用于人和小鼠垂体腺瘤(Donangelo等人,2014; ...

Differentiation of Myeloid-derived Suppressor Cells from Murine Bone Marrow and Their Co-culture with Splenic Dendritic Cells
Author:
Date:
2017-09-20
[Abstract]  Myeloid-derived suppressor cells (MDSCs) possess the ability to suppress the immune response, and to amplify the regulatory properties of other immune cells, i.e., dendritic cells. Here we describe a protocol in which MDSCs were differentiated from murine bone marrow cells, and CD11c+ dendritic cells were purified from murine spleens. MDSCs and CD11c dendritic cells can be co-cultured and the immunoregulatory phenotype of the MDSCs-conditioned dendritic cells could be assessed by means of a specific functional in vivo experiment, i.e., a skin test as a measure of the delayed-type hypersensitivity reaction toward a poorly immunogenic antigen. [摘要]  骨髓来源的抑制细胞(MDSCs)具有抑制免疫应答的能力,并扩增其他免疫细胞即树突状细胞的调节特性。 在这里,我们描述了MDSC与鼠骨髓细胞分化的方案,并且从鼠脾中纯化CD11c +树突状细胞。 可以共培养MDSC和CD11c树突状细胞,并且可以通过特定的功能体内实验来评估MDSCs条件树突细胞的免疫调节表型,即皮肤试验作为延迟型超敏反应的量度 抗免疫原性较差的抗原。
【背景】骨髓来源的抑制细胞(MDSCs)是由早期分化阶段的巨噬细胞,粒细胞,树突状细胞和骨髓细胞的前体组成的骨髓细胞组(Youn等人,2008),其在肿瘤的淋巴组织中大量积累感染性小鼠以及感染性疾病,败血症和创伤的小鼠。这些细胞的主要特征是它们以Ag特异性和/或非特异性方式抑制T细胞应答的能力。这些细胞现在被认为是负责肿瘤相关免疫缺陷的主要细胞类型之一;涉及MDSC介导的免疫抑制的主要因素包括Arg1的高表达(Marvel和Gabrilovich,2015)。精氨酸酶1(Arg1)和吲哚胺2,3-双加氧酶1(IDO1)分别是催化L-精氨酸(L-Arg)和L-色氨酸(L-Trp)降解的免疫调节酶,导致局部氨基酸剥夺。此外,与Arg1不同,IDO1在树突细胞(DC)中也具有非酶信号传导活性(Mondanelli等,2017)。除了其固有的免疫抑制活性外,MDSC还可能扩增其他免疫细胞的调节特性,特别是在肿瘤微环境中。虽然建立了MDSC-巨噬细胞相互作用的一些机制(Ugel等,2015),MDSCs和DCs之间的串扰仍然不清楚(Ostrand-Rosenberg等,2012);为弥补这一差距,我们已经制定了该方案,并且我们证明了Arg1 ...

Comments